Jamjoom Pharma hits limit-up on debut

20/06/2023 Argaam
Logo ofJamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma)

Logo of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) 


Jamjoom Pharmaceuticals Factory Co.’s (Jamjoom Pharma) shares hit limit-up at SAR 78.00 on its first trading session on the Saudi Exchange (Tadawul) today, June 20, compared to the listing price of SAR 60.

 

The stock reached its lowest level today at SAR 66.00.

 

Nearly 879,940 shares worth SAR 68.10 million were traded through 7,849 transactions, so far.

 

Stock Performance During the Trading Session

Listing Price

SAR 60.00

--

Closing Price

SAR 78.00

(+30% compared to listing price)

Highest Price

SAR 78.00

(+30% compared to listing price)

Lowest Price

SAR 66.00

(+10% compared to listing price)

Trading Volume

978,390 shares

About 5% of the total IPO shares

Trading Value

SAR 75.78 mln

--

 

Jamjoom Pharma shares started trading on Tadawul today under the symbol 4015  and ISIN code SA15QGU1UNH6, at SAR 60.

 

Shares are traded with ±30% daily and ±10% static price fluctuation limits. From the fourth trading day onwards, the daily price fluctuation limits will revert to +/-10%, while the static price fluctuation limits will no longer apply.

 

The company offered 21 million shares, or 30% of its capital, at SAR 60 per share. 90% of offered shares were allocated to participating parties, while the remaining 10% were allocated to retail investors.

 

The retail coverage reached 11×, while the tranche of participating parties was 67.2× subscribed  (or 88× if key investors’ allocated shares are excluded).

 

A total of 170,500 retail investors submitted applications for shares worth about SAR 1.39 billion.

 

Each retail investor received a minimum of one share, while the remaining shares will be allocated pro-rata based on the demand size of every subscriber to total shares. The allotment ratio amounted to 0. .5146%.

Comments {{getCommentCount()}}

Be the first to comment

loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.